New research has highlighted the difficulties and distress people experienced when trying to get support after the death of a loved one during the pandemic, with more than half of people (51%) experiencing high or severe ...
Jun 15, 2021
0
1
After being diagnosed with bladder cancer, some patients face an almost impossible decision—have their bladder removed or take a risk knowing that the cancer may be more likely to spread if the bladder is left intact.
Jun 7, 2021
0
8
For the first time, scientists have examined how the three-dimensional (3D) structure of a patient's genome can contribute to bladder cancer and pediatric brain tumors, according to a pair of Northwestern Medicine studies ...
Jun 4, 2021
0
13
New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo) after bladder cancer surgery reduced their overall risk ...
Jun 4, 2021
0
12
A phase 3 clinical trial co-led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients who are at high risk of their cancer returning ...
Jun 2, 2021
0
2
May is Bladder Cancer Awareness Month, which makes this a good time to learn more about bladder cancer.
May 18, 2021
0
3
A protein variant common in malignant bladder tumor cells may serve as a new avenue for treating bladder cancer. A multi-institution study led by UC Davis Comprehensive Cancer Center researchers found that targeting androgen ...
Apr 28, 2021
0
13
Marc Baum went through all the usual steps to treat his bladder cancer—a couple of surgeries, radiation therapy and chemotherapy, all in a three-month period.
Apr 13, 2021
0
29
A new research study leveraging a database from the largest equal access health system in the US, the Department of Veteran Affairs, offers insight into the outcome of specific treatment patterns for advanced bladder cancer ...
Apr 1, 2021
0
2
A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types, according to a new ...
Mar 15, 2021
1
28
